Introducing LifeSciBench

OpenAI’s LifeSciBench signals tightening benchmarks for AI in specialized life sciences. In 2026, this directly impacts the AI economy by raising the entry bar for FDA-adjacent workflows and drug discovery models. Vendors must prove expert-level reliability—not just speed—to capture pharma contracts. Expect higher compliance costs but a clear premium for validated systems, reshaping B2B AI market dynamics.